## Clindamycin

**Section:** Anti-infective medicines > Antibacterials > Access group antibiotics

### Indication

<table>
<thead>
<tr>
<th>Indication</th>
<th>Clindamycin</th>
<th>ICD11 code: FB85</th>
</tr>
</thead>
</table>

### INN

Clindamycin

### Medicine type

Chemical agent

### Antibiotic groups

ACCESS

### List type

Core

### Formulations

- **Parenteral > General injections > IV:** 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate) (EML); 900 mg per 6 mL (as phosphate) (EML)
- **Oral > Liquid:** 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) (EMLc)
- **Oral > Solid:** 150 mg (as hydrochloride)

### EML status history

- First added in 2017 (TRS 1006)
- Changed in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

### Sex

All

### Age

Also recommended for children

### Therapeutic alternatives

The recommendation is for this specific medicine

### Patent information

- Patents have expired in most jurisdictions
- Read more about patents.

### Wikipedia

Clindamycin

### DrugBank

Clindamycin

---

**Expert Committee recommendation**

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - replacing the oral liquid formulation of clindamycin (oral liquid 75 mg/5 mL) with powder for oral liquid 75 mg/5 mL (as palmitate hydrochloride) on the EML and EMLc. - the addition of new strength formulations of cloxacillin (capsule 250 mg, powder for injection 250 mg (as sodium) and powder for oral liquid 250 mg/5 mL (as sodium) on the EMLc.

**EML recommendations: Osteomyelitis or osteitis**

<table>
<thead>
<tr>
<th>First choice</th>
<th>Second choice</th>
</tr>
</thead>
<tbody>
<tr>
<td>cloxacillin</td>
<td>cefazolin</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>clindamycin</td>
<td>cefotaxime</td>
</tr>
<tr>
<td>ceftriaxone</td>
<td>amoxicillin + clavulanic acid</td>
</tr>
</tbody>
</table>